Published 5 days ago • loading... • Updated 5 days ago

MAIA Biotechnology Announces Private Placement of $2,715,000

Summary by Intelligence360 News

February 18, 2025 03:44 PM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,810,000 shares of common stock at a purchase price of $1.50 per share, in a private placement to accre…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

channelchek.com

MAIA Biotechnology (MAIA) - Phase 2 THIO-101 Expansion and Registration Treatment Plans Announced - Channelchek

Thursday, February 27, 2025 MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positiv…

5 days ago

Read Full Article